Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 100 of 256 for:    Anti-Infective Agents AND Antibiotics, Antitubercular AND broad

MALDITOF Versus Routine Clinical Microbiology for Identifying Pathogens; a Randomized Diagnostic Trial (MALDITOF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02306330
Recruitment Status : Completed
First Posted : December 3, 2014
Last Update Posted : November 15, 2016
Sponsor:
Collaborators:
National Hospital for Tropical Diseases, Hanoi, Vietnam
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
Information provided by (Responsible Party):
Oxford University Clinical Research Unit, Vietnam

Brief Summary:
MALDI-TOF MS is capable of directly identifying bacteria and fungi in positive blood cultures, which may be beneficial to patient management. Therefore, MALDI-TOF MS is an important new technology that is becoming routine in developed countries. It is currently unknown whether MALDITOF MS improves diagnostics, costs and patient outcomes in developing countries. This study will assess the clinical impact of a MALDITOF MS system (Maldi Biotyper, Bruker, Germany) in the resource constrained setting of Vietnam and at what cost.

Condition or disease Intervention/treatment Phase
Bacterial Infections Fungal Infections Device: Malditof Other: Routine clinical microbiology Not Applicable

Detailed Description:

When an eligible specimen from a patient shows pathogen growth, the pathogen identification will be randomized to either MaldiTof or routine diagnostics ('diagnostic pipelines'). Randomization to MaldiTof or routine diagnostics will be 1:1 with stratification by hospital and specimen type (blood vs. other). Isolates grown from all eligible specimens of the same patient will be assigned to the same diagnostic pipeline as the first randomized specimen of that patient.

Allocation to diagnostic arm will be assigned by a web based randomization program. When a pathogen is isolated from a positive eligible specimen, the laboratory technician will log onto the secure randomization program and enter the patient and specimen code. The random diagnostic pipeline allocation will then be generated, informed to the laboratory technician and logged in the study database. In the case of multiple specimens with pathogen growth for a single patient, the unique patient code will trigger the randomization program to generate the same diagnostic arm allocation as the previous sample(s).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 802 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: Assessing Time to Reporting and Clinical Management of Patients With Severe Bacterial and Fungal Infections Between Two Diagnostic Approaches: Matrix-assisted Laser Desorption Ionization-time of Flight Mass Spectrometry Versus Routine Clinical Microbiology for Identifying Pathogens; a Randomized Diagnostic Trial
Study Start Date : December 2014
Actual Primary Completion Date : January 2016
Actual Study Completion Date : January 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Molds

Arm Intervention/treatment
Experimental: Malditof
Specimens of patients (diagnostic aspirates from normally sterile sites: cerebrospinal fluid (CSF), deep abscesses, joint fluid, peritoneal fluid, and pleural fluid, deep tissue biopsies) in Malditof arm will be performed by Malditof instrument to identify the pathogens. It takes 20 minutes for Malditof to identify the pathogens. Then patients will be treated based on these results.
Device: Malditof
Malditof MS system is applied for Malditof group for identifying pathogens. It takes 20 minutes to give the results.

Active Comparator: Routine clinical microbiology
Specimens of patients (diagnostic aspirates from normally sterile sites: cerebrospinal fluid (CSF), deep abscesses, joint fluid, peritoneal fluid, and pleural fluid, deep tissue biopsies) in routine clinical microbiology arm will be conducted by the routine clinical microbiologies and followed the treatment process of the hospital.
Other: Routine clinical microbiology
Pathogens will be identified by the routine clinical microbiology of the hospital.




Primary Outcome Measures :
  1. Proportion of patients on optimal antibiotic treatment [ Time Frame: Within 24 hours of positive culture (first growth of an eligible specimen). ]
    Optimal antibiotic treatment is defined as an antibiotic treatment for at least 48 hours since positive culture, targeted to the identified pathogen and later found to cover the organisms antimicrobial resistance profile, while avoiding unnecessary broad spectrum antibiotics (e.g. avoid carbapenems or multiple agents where other agents or single agents would provide sufficient coverage). This study aims to determine The proportion of patients on optimal antibiotic treatment within 24 hours of positive culture (first growth of an eligible specimen).


Secondary Outcome Measures :
  1. The total duration of antibiotic treatment [ Time Frame: During treatment course, estimated to be 7-10 days. ]
  2. The total number of antibiotic switches [ Time Frame: During treatment course, estimated to be 7-10 days. ]
  3. Length of ICU stay [ Time Frame: During ICU admission, estimated to be 7 days ]
  4. Length of hospital stay [ Time Frame: During hospital admission, estimated to be 12 days ]
  5. Patient outcome: death, palliative discharge, survived with sequelae, recovered [ Time Frame: On or before discharge, estimated to be at 12 days ]
  6. Costs of microbiological testing [ Time Frame: On or before discharge, estimated to be at 12 days ]
  7. Treatment and hospital costs [ Time Frame: On or before discharge, estimated to be at 12 days ]

Other Outcome Measures:
  1. Time from first growth of an eligible specimen to optimal antibiotic treatment. [ Time Frame: During hospital admission, estimated to be 0-48 hours ]
  2. Time from specimen collection of positive eligible specimen to optimal antibiotic treatment [ Time Frame: During hospital admission, estimated to be 0-48 hours ]
  3. The time from first recognition of isolate growth to issue of pathogen identification report [ Time Frame: Estimated 0-12 hours ]
  4. The time from specimen collection to issue of pathogen identification report [ Time Frame: Estimated 24-48 hours ]
  5. Time from first specimen collection to discharge [ Time Frame: Estimated to be 12 days ]
  6. Time from first pathogen identification to discharge [ Time Frame: Estimated to be 10 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: Pathogen isolates from the following specimens: blood or diagnostic aspirates from normally sterile sites (including cerebrospinal fluid (CSF), deep abscesses, joint fluid, peritoneal fluid, and pleural fluid, deep tissue biopsies).

Exclusion Criteria:

  • Specimens negative for all pathogens
  • Specimens from sputum, respiratory or non-surgical wound swabs, nails, mucosal or skin biopsies, urine, fluid from drains, skin swabs and any others not listed in the inclusion criteria.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02306330


Locations
Layout table for location information
Vietnam
National Hospital for Tropical Diseases
Ha Noi, Vietnam
Hospital for Tropical Diseases
Ho CHi Minh City, Vietnam
Sponsors and Collaborators
Oxford University Clinical Research Unit, Vietnam
National Hospital for Tropical Diseases, Hanoi, Vietnam
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
Investigators
Layout table for investigator information
Principal Investigator: Heiman Wertheim, MD, PhD Oxford University of Clinical Research

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Oxford University Clinical Research Unit, Vietnam
ClinicalTrials.gov Identifier: NCT02306330     History of Changes
Other Study ID Numbers: 09HN
First Posted: December 3, 2014    Key Record Dates
Last Update Posted: November 15, 2016
Last Verified: December 2014
Keywords provided by Oxford University Clinical Research Unit, Vietnam:
Malditof
Malditof MS
matrix-assisted laser desorption ionization-time
identifying pathogens
randomized diagnostic trial
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Bacterial Infections
Mycoses